Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN7A | Q01118 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26132552 | 0.86 | ALDH1A1 (0.51) | ALDH1A1CYP3A4HSD17B10CYP2C9TSHR | |
| SCHEMBL16372067 | 0.84 | ALDH1A1 (0.54) | SCN7AKCNH2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL30928344 | 0.82 | SCN7A (0.50) | SCN7AKCNH2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL30611378 | 0.81 | SIGMAR1 (0.42) | SIGMAR1PLD1ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL31732979 | 0.81 | GPR119 (0.38) | SIGMAR1PLD1ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL19617917 | 0.81 | GPR119 (0.38) | SIGMAR1PLD1ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL30237082 | 0.81 | SIGMAR1 (0.41) | SCN7AKCNH2SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30665056 | 0.79 | MKNK1 (0.41) | SIGMAR1ALDH1A1MGLL | |
| SCHEMBL23851281 | 0.77 | KDM4E (0.44) | SIGMAR1ALDH1A1HSD17B10TSHRSMN1; SMN2 | |
| SCHEMBL23850969 | 0.77 | RXFP1 (0.39) | SCN7AKCNH2SIGMAR1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| CN-114599652-B | Hydropyrazino [1,2-d ] [1,4] diazepine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023207284-A1 | PIPERAZINE DERIVATIVES AS PARP1 INHIBITIORS | NINGBO NEWBAY TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2023-11-02 | — | — | WO | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-03-23 | — | — | US | disclosed |
| CN-114901277-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2017216726-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | AR, ADRM1, PSMA1 | SCN7A 2973/4885KCNH2 4759/4885SIGMAR1 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.